Skip to main content
. Author manuscript; available in PMC: 2005 Oct 17.
Published in final edited form as: Am J Addict. 2004;13(Suppl 1):S42–S66. doi: 10.1080/10550490490440807

FIGURE 2.

FIGURE 2

Percent of randomized patients who received a dose of buprenorphine-naloxone and any type of ancillary medication on each day of the dose taper for Insomnia (closed square); Anxiety and Restlessness (open diamond); Bone Pain and Arthralgias (open circle); Nausea (closed triangle); or Diarrhea (closed circle).

HHS Vulnerability Disclosure